Beryl Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Beryl Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-13,680	Closed	-$1.36M	–	227
2021 Q2	$1.36M	Sell	13,680 -12,500	-48%	-$1.24M	0.12%	152
2021 Q1	$2.59M	Buy	26,180 +668	+3%	+$67.9K	0.33%	91
2020 Q4	$2.55M	Hold	25,512	–	–	0.4%	94
2020 Q3	$2.53M	Buy	25,512 +16,221	+175%	+$1.62M	0.46%	41
2020 Q2	$952K	Buy	+9,291	New	+$908K	0.18%	38

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Beryl Capital Management's JSPR Position: Q3 2021 in Review

Beryl Capital Management sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 13,680 shares — an estimated $1.36M sold.

Beryl Capital Management first reported a position in JSPR in Q2 2020 and held it in 5 quarters. The position peaked at $2.59M in Q1 2021. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

Beryl Capital Management reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
Beryl Capital Management sold 13,680 Jasper Therapeutics shares in Q3 2021, an estimated $1.36M.
Beryl Capital Management first reported a position in Jasper Therapeutics in Q2 2020 and held it in 5 quarters.
Beryl Capital Management's Jasper Therapeutics position peaked at $2.59M in Q1 2021.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Beryl Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.